Quantitative Measurements of Tumoral p95HER2 Protein Expression in Metastatic Breast Cancer Patients Treated with Trastuzumab: Independent Validation of the p95HER2 Clinical Cutoff

Duchnowska Renata; Sperinde Jeff; Chenna Ahmed; Haddad Mojgan; Paquet Agnes; Lie Yolanda; Weidler Jodi M.; Huang Weidong; Winslow John; Jankowski Tomasz; Czartoryska-Arlukowicz Bogumila; Wysocki Piotr J.; Foszczynska-Kloda Malgorzata; Radecka Barbara; Litwiniuk Maria M.; Zok Jolanta; Wisniewski Michal; Zuziak Dorota; Biernat Wojciech; Jassem Jacek

首页> 外文期刊>Clinical cancer research: an official journal of the American Association for Cancer Research >Quantitative Measurements of Tumoral p95HER2 Protein Expression in Metastatic Breast Cancer Patients Treated with Trastuzumab: Independent Validation of the p95HER2 Clinical Cutoff

【24h】

Quantitative Measurements of Tumoral p95HER2 Protein Expression in Metastatic Breast Cancer Patients Treated with Trastuzumab: Independent Validation of the p95HER2 Clinical Cutoff

机译：曲妥珠单抗治疗转移性乳腺癌患者肿瘤p95HER2蛋白表达的定量测量：p95HER2临床临界值的独立验证

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Purpose: P95HER2 (p95) is a truncated form of the HER2, which lacks the trastuzumab-binding site and contains a hyperactive kinase domain. Previously, an optimal clinical cutoff of p95 expression for progression-free survival (PFS) and overall survival (OS) was defined using a quantitative VeraTag assay (Monogram Biosciences) in a training set of trastuzumab-treated metastatic breast cancer (MBC) patients.

机译：目的：P95HER2（p95）是HER2的截短形式，它缺少曲妥珠单抗结合位点，并含有一个过度活跃的激酶结构域。以前，在一组接受曲妥珠单抗治疗的转移性乳腺癌（MBC）患者中，使用定量VeraTag测定法（Monogram Biosciences）定义了无进展生存期（PFS）和总生存期（OS）的p95表达的最佳临床临界值。

著录项

来源
《Clinical cancer research: an official journal of the American Association for Cancer Research》 |2014年第10期|共9页
作者
Duchnowska Renata; Sperinde Jeff; Chenna Ahmed; Haddad Mojgan; Paquet Agnes; Lie Yolanda; Weidler Jodi M.; Huang Weidong; Winslow John; Jankowski Tomasz; Czartoryska-Arlukowicz Bogumila; Wysocki Piotr J.; Foszczynska-Kloda Malgorzata; Radecka Barbara; Litwiniuk Maria M.; Zok Jolanta; Wisniewski Michal; Zuziak Dorota; Biernat Wojciech; Jassem Jacek;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Quantitative Measurements of Tumoral p95HER2 Protein Expression in Metastatic Breast Cancer Patients Treated with Trastuzumab: Independent Validation of the p95HER2 Clinical Cutoff [J] . Duchnowska Renata, Sperinde Jeff, Chenna Ahmed, Clinical cancer research: an official journal of the American Association for Cancer Research . 2014,第10期

机译：曲妥珠单抗治疗转移性乳腺癌患者肿瘤p95HER2蛋白表达的定量测量：p95HER2临床临界值的独立验证
2. Clinical significance of p95HER2 overexpression, PTEN loss and PI3K expression in p185HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies [J] . D Tural, S Serdengecti, F Demirelli, British Journal of Cancer . 2014,第12期

机译：曲妥珠单抗治疗的p185HER2阳性转移性乳腺癌患者中p95HER2过表达，PTEN缺失和PI3K表达的临床意义
3. Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization-positive patients with metastatic breast cancer treated with trastuzumab. [J] . Lipton A, Kostler WJ, Leitzel K, Cancer: A Journal of the American Cancer Society . 2010,第22期

机译：定量HER2蛋白水平可预测曲妥珠单抗治疗的转移性乳腺癌荧光原位杂交阳性患者的预后。
4. Measurement of Human Breast Tumor Cell-Secreted shNDPK-B in a Murine Breast Cancer Model Suggests its Role in Metastatic Progression [C] . Nucharee Yokdang, Noah D. Buxton and lain L. 0. Buxton* Western Pharmacology Society . 2009

机译：在鼠乳腺癌模型中的人乳腺肿瘤细胞分泌的ShNDPK-B的测量表明其在转移性进展中的作用
5. Toll-like receptor (TLR) expression and function of immune system cells from metastatic breast cancer patients with circulating tumor cells. [D] . Green, Taryn Lindsey. 2013

机译：Toll样受体（TLR）的表达和具有循环肿瘤细胞的转移性乳腺癌患者免疫系统细胞的功能。
6. Clinical significance of p95HER2 overexpression PTEN loss and PI3K expression in p185HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies [O] . D Tural, S Serdengecti, F Demirelli, 2014

机译：曲妥珠单抗治疗的p185HER2阳性转移性乳腺癌患者中p95HER2过表达PTEN缺失和PI3K表达的临床意义
7. Predictive value of quantitative HER2, HER3 and p95HER2 levels in HER2-positive advanced breast cancer patients treated with lapatinib following progression on trastuzumab [O] . Renata Duchnowska, Jeff Sperinde, Bogumiła Czartoryska-Arłukowicz, 2017

机译：在曲妥珠替纳布进展后，在曲妥替尼替税后治疗HER2阳性晚期乳腺癌患者的定量HER2，HER3和P95HEH2水平的预测值

Quantitative Measurements of Tumoral p95HER2 Protein Expression in Metastatic Breast Cancer Patients Treated with Trastuzumab: Independent Validation of the p95HER2 Clinical Cutoff

摘要

著录项

相似文献

相关主题

期刊订阅